PROCEPT BioRobotics Corp
About PROCEPT BioRobotics Corp
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $308.1M
- Net income
- -$95.6M
- Total assets
- $508.1M
- Market cap
- $1.6B
- Gross margin
- 63.7%
- Operating margin
- -33.7%
- Net margin
- -31.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $308.1M
- Cost of revenue
- $111.8M
- Gross profit
- $196.2M
- Operating expenses
- $300.1M
- Operating income
- -$103.9M
- Income tax
- $190.0K
- Net income
- -$95.6M
- EPS (basic)
- $-1.72
- EPS (diluted)
- $-1.72
Balance sheet
- Total assets
- $508.1M
- Current assets
- $450.4M
- Total liabilities
- $142.2M
- Current liabilities
- $65.8M
- Shareholders’ equity
- $365.9M
Cash flow
- Operating cash flow
- -$49.0M
- Investing cash flow
- -$9.4M
- Financing cash flow
- $11.2M
- Net cash flow
- -$47.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.6B
- EPS (diluted)
- $-1.72
- Shares outstanding
- 55.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 15, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $95.6M in FY2025.
- Revenue grew 794% from FY2021 to FY2025.
- Gross margin of 63.7%, net margin -31.0%.
- Trading 56% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review PROCEPT BioRobotics Corp.
Write a review
News about PROCEPT BioRobotics Corp
News & sentiment via Polygon.io
